AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
AbCellera Biologics Inc. - Common Shares (ABCL)
Company Research
Source: Business Wire
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology.The collaboration brings together Viking and ArrowMark’s expertise in early-stage investing and company creation with AbCellera’s engine for discovering and developing antibody medicines. Under the collaboration, ArrowMark and Viking will lead the initial process of program selection, followed by joint determination of the therapeutic product profile and AbCellera’s initiation of new antibody drug programs. AbCellera will advance programs to development candidates and has an option to conduct cGMP manufacturing to support Phase 1 clinical trials. Successful programs will be further developed through the creation of Newcos, with Vikin
Show less
Read more
Impact Snapshot
Event Time:
ABCL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABCL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABCL alerts
High impacting AbCellera Biologics Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ABCL
News
- Earnings Release: Here's Why Analysts Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$12.71 [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (NASDAQ: ABCL) had its price target lowered by analysts at KeyCorp from $8.00 to $7.00. They now have an "overweight" rating on the stock.MarketBeat
- AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ABCL
Earnings
- 5/7/24 - Beat
ABCL
Sec Filings
- 5/7/24 - Form 10-Q
- 5/7/24 - Form 8-K
- 4/29/24 - Form ARS
- ABCL's page on the SEC website